

Lanfranco Fattorini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7981850/publications.pdf>

Version: 2024-02-01

105
papers

4,274
citations

109321

35
h-index

123424

61
g-index

106
all docs

106
docs citations

106
times ranked

5110
citing authors

#	ARTICLE	IF	CITATIONS
1	Activity of Drug Combinations against <i>Mycobacterium abscessus</i> Grown in Aerobic and Hypoxic Conditions. <i>Microorganisms</i> , 2022, 10, 1421.	3.6	4
2	Moxifloxacin Activates the SOS Response in <i>Mycobacterium tuberculosis</i> in a Dose- and Time-Dependent Manner. <i>Microorganisms</i> , 2021, 9, 255.	3.6	13
3	The Antimalarial Mefloquine Shows Activity against <i>Mycobacterium abscessus</i> , Inhibiting Mycolic Acid Metabolism. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8533.	4.1	4
4	<i>Mycobacterium tuberculosis</i> and SARS-CoV-2 Coinfections: A Review. <i>Frontiers in Microbiology</i> , 2021, 12, 747827.	3.5	11
5	Drug-Resistant Tuberculosis 2020: Where We Stand. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2153.	2.5	46
6	Bacterial coinfections in COVID-19: an underestimated adversary. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2020, 56, 359-364.	0.4	55
7	The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant <i>Mycobacterium tuberculosis</i> in Hypoxia at Neutral pH. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	13
8	A Rapid Unraveling of the Activity and Antibiotic Susceptibility of <i>Mycobacteria</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	23
9	Revisiting problems and solutions to decrease <i>Mycobacterium tuberculosis</i> pyrazinamide false resistance when using the Bactec MGIT 960 system. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2019, 55, 51-54.	0.4	4
10	Use of probiotics in medical devices applied to some common pathologies. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2019, 55, 380-385.	0.4	3
11	Trends in the discovery of new drugs for <i>Mycobacterium tuberculosis</i> therapy with a glance at resistance. <i>Tuberculosis</i> , 2018, 109, 17-27.	1.9	47
12	Activity of DNA-targeted C8-linked pyrrolobenzodiazepineâ€“heterocyclic polyamide conjugates against aerobically and hypoxically grown <i>Mycobacterium tuberculosis</i> under acidic and neutral conditions. <i>Journal of Antibiotics</i> , 2018, 71, 831-834.	2.0	3
13	Clofazimine: A useful antibiotic for drug-resistant tuberculosis. <i>Biomedicine and Pharmacotherapy</i> , 2018, 105, 1353-1359.	5.6	48
14	Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009â€“2016. <i>European Respiratory Journal</i> , 2018, 52, 1800070.	6.7	16
15	Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries. <i>European Respiratory Journal</i> , 2017, 49, 1602242.	6.7	11
16	<i>Mycobacterium tuberculosis</i> Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	25
17	Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False <i>Mycobacterium tuberculosis</i> Pyrazinamide Resistance. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3552-3553.	3.9	4
18	Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey. <i>Jornal Brasileiro De Pneumologia</i> , 2017, 43, 380-392.	0.7	26

#	ARTICLE	IF	CITATIONS
19	Fighting tuberculosis by drugs targeting nonreplicating <i>Mycobacterium tuberculosis</i> bacilli. International Journal of Mycobacteriology, 2017, 6, 213.	0.6	29
20	External Quality Assessment for Tuberculosis Diagnosis and Drug Resistance in the European Union: A Five Year Multicentre Implementation Study. PLoS ONE, 2016, 11, e0152926.	2.5	25
21	Activity of drugs against dormant <i>Mycobacterium tuberculosis</i> . International Journal of Mycobacteriology, 2016, 5, S94-S95.	0.6	11
22	Pyrazinamide susceptibility testing: proposed new standard with the BACTEC MGIT 960 system. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1677-1680.	1.2	4
23	<i>Mycobacterium tuberculosis</i> gene expression at different stages of hypoxia-induced dormancy and upon resuscitation. Journal of Microbiology, 2016, 54, 565-572.	2.8	55
24	Tuberculosis in migrants from 106 countries to Italy, 2008-2014. European Respiratory Journal, 2016, 47, 1273-1276.	6.7	12
25	Drug-resistant tuberculosis in Naples, 2008-2013. Annali Dell'Istituto Superiore Di Sanita, 2016, 52, 603-607.	0.4	2
26	Activity of lipophilic and hydrophilic drugs against dormant and replicating <i>Mycobacterium tuberculosis</i> . Journal of Antibiotics, 2015, 68, 711-714.	2.0	61
27	Towards tuberculosis elimination: an action framework for low-incidence countries. European Respiratory Journal, 2015, 45, 928-952.	6.7	608
28	Rifampin Induces Hydroxyl Radical Formation in <i>Mycobacterium tuberculosis</i> . Antimicrobial Agents and Chemotherapy, 2014, 58, 7527-7533.	3.2	91
29	Risk Factors for Tuberculosis in Foreign-Born People (FBP) in Italy: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e94728.	2.5	19
30	Activities of Drug Combinations against <i>Mycobacterium tuberculosis</i> Grown in Aerobic and Hypoxic Acidic Conditions. Antimicrobial Agents and Chemotherapy, 2013, 57, 1428-1433.	3.2	61
31	Prevention of False Resistance Results Obtained in Testing the Susceptibility of <i>Mycobacterium tuberculosis</i> to Pyrazinamide with the Bactec MGIT 960 System Using a Reduced Inoculum. Journal of Clinical Microbiology, 2013, 51, 291-294.	3.9	58
32	Whole Genome Sequencing Reveals Complex Evolution Patterns of Multidrug-Resistant <i>Mycobacterium tuberculosis</i> Beijing Strains in Patients. PLoS ONE, 2013, 8, e82551.	2.5	117
33	TARGETING DORMANT BACILLI TO FIGHT TUBERCULOSIS. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013072.	1.3	38
34	Drug-resistant tuberculosis among foreign-born persons in Italy: Table 1. European Respiratory Journal, 2012, 40, 497-500.	6.7	20
35	Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy: Figure 1. European Respiratory Journal, 2012, 39, 1263-1266.	6.7	10
36	GenoType MTBDR performance on clinical samples with diverse genetic background. European Respiratory Journal, 2012, 40, 690-698.	6.7	37

#	ARTICLE	IF	CITATIONS
37	Infection of human THP-1 cells with dormant <i>Mycobacterium tuberculosis</i> . <i>Microbes and Infection</i> , 2012, 14, 959-967.	1.9	31
38	Treatment of Tuberculosis in a Region with High Drug Resistance: Outcomes, Drug Resistance Amplification and Re-Infection. <i>PLoS ONE</i> , 2011, 6, e23081.	2.5	26
39	Activity of Drugs Against Dormant <i>Mycobacterium tuberculosis</i> . <i>Journal of Chemotherapy</i> , 2011, 23, 175-178.	1.5	4
40	Expression of Proinflammatory and Regulatory Cytokines via NF- κ B and MAPK-Dependent and IFN Regulatory Factor-3-Independent Mechanisms in Human Primary Monocytes Infected by <i>Mycobacterium tuberculosis</i> . <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-8.	3.3	14
41	Activity of Drug Combinations against Dormant <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2712-2715.	3.2	34
42	<i>Mycobacterium tuberculosis</i> Strains with Highly Discordant Rifampin Susceptibility Test Results. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3501-3506.	3.9	167
43	IFN- γ improves BCG immunogenicity by acting on DC maturation. <i>Journal of Leukocyte Biology</i> , 2009, 85, 462-468.	3.3	39
44	The <i>Mycobacterium tuberculosis</i> Sigma Factor σ^B Is Required for Full Response to Cell Envelope Stress and Hypoxia In Vitro, but It Is Dispensable for In Vivo Growth. <i>Journal of Bacteriology</i> , 2009, 191, 5628-5633.	2.2	66
45	Characteristics of drug-resistant tuberculosis in Abkhazia (Georgia), a high-prevalence area in Eastern Europe. <i>Tuberculosis</i> , 2009, 89, 317-324.	1.9	38
46	Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. <i>European Respiratory Journal</i> , 2008, 31, 1155-1159.	6.7	131
47	The LTK63 adjuvant improves protection conferred by Ag85B DNA-protein prime-boosting vaccination against <i>Mycobacterium tuberculosis</i> infection by dampening IFN- γ response. <i>Vaccine</i> , 2008, 26, 4237-4243.	3.8	29
48	Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results. <i>Clinical Infectious Diseases</i> , 2008, 46, 958-959.	5.8	35
49	Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2008, 31, 904-905.	6.7	67
50	Clinical and operational value of the extensively drug-resistant tuberculosis definition. <i>European Respiratory Journal</i> , 2007, 30, 623-626.	6.7	179
51	Pyrazinamide Resistance in Multidrug-Resistant Strains of <i>Mycobacterium tuberculosis</i> Isolated in Abkhazia. <i>Journal of Chemotherapy</i> , 2007, 19, 106-107.	1.5	1
52	Metronidazole plus Rifampin Sterilizes Long-Term Dormant <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1537-1540.	3.2	26
53	Isolation of <i>Nocardia asiatica</i> from Cutaneous Ulcers of a Human Immunodeficiency Virus-Infected Patient in Italy. <i>Journal of Clinical Microbiology</i> , 2007, 45, 2088-2089.	3.9	17
54	Usefulness of the BACTEC MGIT 960 System for Isolation of <i>Mycobacterium tuberculosis</i> from Sputa Subjected to Long-Term Storage. <i>Journal of Clinical Microbiology</i> , 2007, 45, 575-576.	3.9	8

#	ARTICLE	IF	CITATIONS
55	Validation of the agar proportion and 2 liquid systems for testing the susceptibility of Mycobacterium tuberculosis to moxifloxacin. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, 283-287.	1.8	8
56	The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice. <i>Cellular Microbiology</i> , 2007, 9, 1455-1465.	2.1	38
57	Immune response and protection by DNA vaccines expressing antigen 85B of Mycobacterium tuberculosis. <i>FEMS Microbiology Letters</i> , 2006, 262, 210-215.	1.8	9
58	Infection of Human Dendritic Cells with a Mycobacterium tuberculosis sigE Mutant Stimulates Production of High Levels of Interleukin-10 but Low Levels of CXCL10: Impact on the T-Cell Response. <i>Infection and Immunity</i> , 2006, 74, 3296-3304.	2.2	24
59	Evaluation of Molecular-Beacon, TaqMan, and Fluorescence Resonance Energy Transfer Probes for Detection of Antibiotic Resistance-Confering Single Nucleotide Polymorphisms in Mixed Mycobacterium tuberculosis DNA Extracts. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3826-3829.	3.9	28
60	<i>Mycobacterium tuberculosis</i> Drug Resistance, Abkhazia. <i>Emerging Infectious Diseases</i> , 2005, 11, 501-503.	4.3	12
61	Evaluation of a New Line Probe Assay for Rapid Identification of gyrA Mutations in Mycobacterium tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2928-2933.	3.2	49
62	Cetyl-Pyridinium Chloride Is Useful for Isolation of Mycobacterium tuberculosis from Sputa Subjected to Long-Term Storage. <i>Journal of Clinical Microbiology</i> , 2005, 43, 442-444.	3.9	33
63	Drug Resistance Evolution of a Mycobacterium tuberculosis Strain from a Noncompliant Patient. <i>Journal of Clinical Microbiology</i> , 2005, 43, 3114-3120.	3.9	45
64	Mycobacterium bovis Bacillus Calmette-Guerin infects DC-SIGN- dendritic cell and causes the inhibition of IL-12 and the enhancement of IL-10 production. <i>Journal of Leukocyte Biology</i> , 2005, 78, 106-113.	3.3	51
65	A Pyrosequencing assay for rapid recognition of SNPs in Mycobacterium tuberculosis embB306 region. <i>Journal of Microbiological Methods</i> , 2005, 62, 113-120.	1.6	38
66	Mycobacterium tuberculosis Complex Drug Resistance in Italy. <i>Emerging Infectious Diseases</i> , 2004, 10, 752-753.	4.3	7
67	Inhibition of HIV-1 Replication in Monocyte-Derived Macrophages by Mycobacterium tuberculosis. <i>Journal of Infectious Diseases</i> , 2004, 189, 624-633.	4.0	39
68	The Extra Cytoplasmic Function Sigma Factor σ^E Is Essential for Mycobacterium tuberculosis Virulence in Mice. <i>Infection and Immunity</i> , 2004, 72, 3038-3041.	2.2	90
69	Mycobacterium tuberculosis Diverts Alpha Interferon-Induced Monocyte Differentiation from Dendritic Cells into Immunoprivileged Macrophage-Like Host Cells. <i>Infection and Immunity</i> , 2004, 72, 4385-4392.	2.2	48
70	Induction of Mycobacterium avium proteins upon infection of human macrophages. <i>Proteomics</i> , 2004, 4, 3078-3083.	2.2	12
71	In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis. <i>Peptides</i> , 2004, 25, 1075-1077.	2.4	56
72	Bacillus Calmette-Guérin shares with virulent the capacity to subvert monocyte differentiation into dendritic cell: implication for its efficacy as a vaccine preventing tuberculosis. <i>Vaccine</i> , 2004, 22, 3848-3857.	3.8	28

#	ARTICLE	IF	CITATIONS
73	Activities of Moxifloxacin Alone and in Combination with Other Antimicrobial Agents against Multidrug-Resistant <i>Mycobacterium tuberculosis</i> Infection in BALB/c Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 360-362.	3.2	51
74	Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998-2000. <i>European Respiratory Journal</i> , 2003, 21, 129-134.	6.7	12
75	An Anti-Inflammatory Role for $V\alpha 14$ NK T cells in <i>Mycobacterium bovis</i> /Bacillus Calmette-Guèrin-Infected Mice. <i>Journal of Immunology</i> , 2003, 171, 1961-1968.	0.8	61
76	<i>Mycobacterium tuberculosis</i> subverts the differentiation of human monocytes into dendritic cells. <i>European Journal of Immunology</i> , 2002, 32, 3050-3058.	2.9	79
77	Recombinant GroES in combination with CpG oligodeoxynucleotides protects mice against <i>Mycobacterium avium</i> infection. <i>Journal of Medical Microbiology</i> , 2002, 51, 1071-1079.	1.8	7
78	Exposure of BALB/c mice to low doses of <i>Mycobacterium avium</i> increases resistance to a subsequent high-dose infection. <i>Microbiology (United Kingdom)</i> , 2002, 148, 3173-3181.	1.8	3
79	Involvement of the <i>fadD33</i> gene in the growth of <i>Mycobacterium tuberculosis</i> in the liver of BALB/c mice. <i>Microbiology (United Kingdom)</i> , 2002, 148, 3873-3880.	1.8	32
80	Infection of Human Macrophages and Dendritic Cells with <i>Mycobacterium tuberculosis</i> Induces a Differential Cytokine Gene Expression That Modulates T Cell Response. <i>Journal of Immunology</i> , 2001, 166, 7033-7041.	0.8	378
81	<i>Bacillus Calmette-Guèrin</i> Down-Regulates CD1b Induction by Granulocyte-Macrophage Colony Stimulating Factor in Human Peripheral Blood Monocytes. <i>Journal of Chemotherapy</i> , 2001, 13, 52-58.	1.5	9
82	Influence of <i>Mycobacterium bovis</i> Bacillus Calmette Guèrin on In Vitro Induction of CD1 Molecules in Human Adherent Mononuclear Cells. <i>Infection and Immunity</i> , 2001, 69, 7461-7470.	2.2	21
83	Virulence and drug susceptibility of <i>Mycobacterium celatum</i> . <i>Microbiology (United Kingdom)</i> , 2000, 146, 2733-2742.	1.8	17
84	<i>Mycobacterium avium</i> infection in BALB/c and SCID mice. <i>Journal of Medical Microbiology</i> , 1999, 48, 577-583.	1.8	4
85	Activity of 16 Antimicrobial Agents Against Drug-Resistant Strains of <i>Mycobacterium tuberculosis</i> . <i>Microbial Drug Resistance</i> , 1999, 5, 265-270.	2.0	33
86	Activities of Eighteen Antimicrobial Regimens against <i>Mycobacterium avium</i> Infection in Beige Mice. <i>Microbial Drug Resistance</i> , 1999, 5, 227-233.	2.0	2
87	Upregulation of p75 Tumor Necrosis Factor Alpha Receptor in <i>Mycobacterium avium</i> -Infected Mice: Evidence for a Functional Role. <i>Infection and Immunity</i> , 1999, 67, 5762-5767.	2.2	13
88	Activities of Isoniazid Alone and in Combination with Other Drugs against <i>Mycobacterium avium</i> Infection in Beige Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 712-714.	3.2	9
89	Non-inducible, mainly cell-associated beta-lactamase from <i>Nocardia asteroides</i> strain 108. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 5-11.	3.0	7
90	Type Frequency and Antimicrobial Susceptibility of <i>Mycobacterium avium</i> -intracellulare Complex Strains Isolated in Italy from AIDS and Non-AIDS Patients. <i>Journal of Chemotherapy</i> , 1996, 8, 37-42.	1.5	20

#	ARTICLE	IF	CITATIONS
91	Late Acquisition of Hyporesponsiveness to Lipopolysaccharide by Mycobacterium avium-Infected Human Macrophages in Producing Tumor Necrosis Factor- α but Not Interleukin- 1α and -6. Journal of Infectious Diseases, 1996, 173, 1030-1034.	4.0	7
92	In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium. Antimicrobial Agents and Chemotherapy, 1995, 39, 680-685.	3.2	34
93	Antigenic properties and immunoelectron microscopic localization of Mycobacterium fortuitum beta-lactamase. Antimicrobial Agents and Chemotherapy, 1995, 39, 739-745.	3.2	21
94	Identification of Mycobacterium tuberculosis complex, Mycobacterium avium and Mycobacterium intracellulare by selective nested polymerase chain reaction. Molecular and Cellular Probes, 1995, 9, 321-326.	2.1	12
95	Induction of IL- 1α , IL-6, TNF- α , GM-CSF and G-CSF in human macrophages by smooth transparent and smooth opaque colonial variants of Mycobacterium avium. Journal of Medical Microbiology, 1994, 40, 129-133.	1.8	44
96	Use of the chromosomal class A beta-lactamase of Mycobacterium fortuitum D316 to study potentially poor substrates and inhibitory beta-lactam compounds. Antimicrobial Agents and Chemotherapy, 1994, 38, 1608-1614.	3.2	44
97	Transcription and expression analysis, using lacZ and phoA gene fusions, of Mycobacterium fortuitum β -lactamase genes cloned from a natural isolate and a high-level β -lactamase producer. Molecular Microbiology, 1994, 12, 491-504.	2.5	104
98	Activity of Antimicrobial Drugs Evaluated by Agar Dilution and Radiometric Methods against Strains of Nocardia asteroides Isolated in Italy from Immunocompromised Patients. Journal of Chemotherapy, 1994, 6, 29-34.	1.5	12
99	Resistance to beta-lactams in Mycobacterium fortuitum. Antimicrobial Agents and Chemotherapy, 1992, 36, 1068-1072.	3.2	25
100	Activity of Antimicrobial Agents Against Mycobacterium avium-intracellulare Complex (MAC) Strains Isolated in Italy from AIDS-Patients. Zentralblatt Fur Bakteriologie: International Journal of Medical Microbiology, 1992, 276, 512-520.	0.5	6
101	In Vitro Activity of Clarithromycin Alone or in Combination with Other Antimicrobial Agents against Mycobacterium avium-intracellulare Complex Strains Isolated from AIDS Patients. Journal of Chemotherapy, 1991, 3, 357-362.	1.5	9
102	Beta-lactamase of Mycobacterium fortuitum: kinetics of production and relationship with resistance to beta-lactam antibiotics. Antimicrobial Agents and Chemotherapy, 1991, 35, 1760-1764.	3.2	18
103	Characterization of a β -lactamase produced in Mycobacterium fortuitum D316. Biochemical Journal, 1990, 271, 729-734.	3.7	33
104	Inhibitors and Inactivators of Beta-Lactamase from Mycobacterium fortuitum. Journal of Chemotherapy, 1989, 1, 293-297.	1.5	6
105	Induction of Mycobacterium avium proteins upon infection of human macrophages. , 0, , 279-287.		0